Homepage - Ophthalmology Advisor
This Domestic Violence Awareness Month, Psychiatry Advisor spoke with Allison Paugh to discuss best practices when encountering cases of suspected IPV during teletherapy.
Gene Therapy Sustains Acuity in MT-ND4 LHON - Ophthalmology …
Dec 30, 2024 · A gene therapy, lenadogene nolparvovec, can sustain improvement in best-corrected visual acuity (BCVA) for up to 5 years in patients with MT-ND4 Leber hereditary optic neuropathy (LHON), according to research published in JAMA Ophthalmology.The therapy also demonstrates a favorable safety profile, according to the report.
Ophthalmology Advisor Redesign: New Look, Better Access, …
Sep 12, 2022 · Welcome to the new Ophthalmology Advisor! As you can see, we’ve completely redesigned the site with a sleeker, more modern feel to better fit our top-quality and comprehensive eye care coverage.
Intraocular Lens Choice Dependent on Lifestyle, Expectations ...
Oct 4, 2024 · Cataract surgeons are responsible for advising patients on a decision that will have lifelong implications. Identifying the intraocular lens (IOL) choice most suited for a particular patient’s lifestyle should be done with the patient’s careful consideration, and full understanding of the portfolio of options before them.
Treatment Burden Reduction in Retinal Care a Prime Focus At AAO ...
Nov 1, 2024 · It was 20 years ago, not quite today, that the first anti-vascular endothelial growth factor (VEGF) agent was approved for ophthalmic use. 1 And while these drugs did create a whole new paradigm for treating age-related macular degeneration (AMD), diabetic macular edema (DME), and other retinal conditions, researchers have not spent the last 20 years resting on their laurels.
Photobiomodulation: An Emerging Dry AMD Treatment
Mar 20, 2024 · In exudative age-related macular degeneration (wet AMD), significant strides — such as the development of anti-vascular endothelial growth factor (anti-VEGF) therapies — have pushed the treatment possibilities forward and rewritten the likely course of the disease for many patients. However, for most patients, AMD is nonexudative (dry), and treatments for those patients remain largely ...
Faricimab Therapy Shows Stable Vision At 1 Year - Ophthalmology …
Dec 3, 2024 · With intravitreal faricimab therapy, a real-world cohort achieved steady mean treatment extension and reduced subretinal fluid (SRF), while preserving vision — despite their neovascular age-related macular degeneration (nAMD) being chronic and having previously received other maintenance biologics, according to a study in Retina.. Investigators reviewed charts of 217 participants (263 eyes ...
FDA Alerts: Ophthalmology Drug and Device Approvals
Feb 20, 2024 · Drug Regulatory Updates. Susvimo: Diabetic Eye Conditions. The FDA has accepted the application for Susvimo ® (ranibizumab injection, Genentech) to treat diabetic macular edema (DME) and diabetic retinopathy (DR) based on 1-year Pagoda and Pavilion study data. 3 Susvimo is a refillable implant that delivers medication continuously. 3. Based on 2 years of Phase 3 data presented at American ...
Polygenic Risk Score Predicts Risk for POAG - Ophthalmology …
Nov 11, 2024 · A polygenic risk score (PRS) threshold can identify individuals at high and low risk for developing primary open-angle glaucoma (POAG), according to research published in JAMA Ophthalmology.. Researchers conducted a post hoc analysis of the Ocular Hypertension Treatment Study (OHTS) (ClinicalTrials.gov Identifier: NCT00000125), a multicenter randomized clinical trial of 1636 participants with ...
Stent Implant Efficacy Higher Without Cataract Surgery
Jun 25, 2024 · The Xen 45 gel stent implant provides effective, long-term treatment for open-angle glaucoma but there is a substantial rate of reoperation and needling, according to research published in British Journal of Ophthalmology.. The FDA approved the Xen 45 gel stent implant through the 510k pathway.